Using C. Elegans to search for anti-helminth compounds

Status
Completed
Start date
End date
Start stage
Screening
End stage
Screening
Disease
Soil-transmitted helminthiasis (STH)
Research areas
Drug

Dr. Dent (McGill University) had optimized C. elegans as a model system to screen compounds for potential activity against STH. BVGH facilitated a collaboration between Dr. Dent and AstraZeneca, which provided a large compound library for screening. Dr. Dent screened the compounds, and was additionally awarded a travel grant to meet with his collaborators at AstraZeneca’s high-throughput screening facility in the United Kingdom.